Innovative Medicine Shares Pull Back from Highs with Widespread Losses; Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Drops More Than 2.5%

NewTimeSpace News：On April 17, the Hang Seng Biotech Index dropped 2% intraday, with constituent stocks declining broadly. CSPC Pharmaceutical Group fell 3.64%, BeiGene dropped 1.98%, Sino Biopharmaceutical declined 0.98%, Innovent Biologics fell 1.35%, andChinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) plunged over 4%.

Recently, BeiGene released its 2025 annual report, achieving operating revenue of RMB 38.225 billion, up 40.46% year-on-year. The company recorded net profit attributable to shareholders of RMB 1.461 billion, turning profitable compared to a net loss of RMB 4.978 billion in 2024. This marks the first full-year profit since its listing.

According to HKEX data,Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK), issued by CSOP Asset Management (Hong Kong) Limited, is the first ETF in Hong Kong tracking the Hang Seng Hong Kong-Listed Biotech Index, offering first-mover advantages and filling a market gap. The product possesses uniqueness and scarcity in the biotech sector, particularly for Hong Kong-listed biotech companies. The index's top ten constituents include leaders such as WuXi Biologics, BeiGene, and Innovent Biologics. Most of these companies have established solid domestic market shares and demonstrate global competitiveness through continuous R&D investment and overseas licensing partnerships.

According to statistics from the NextPharma database by Medical Cube, Chinese innovative drug outbound BD (business development) transactions this year are notably concentrated in early-stage R&D. As preclinical projects and technology platform collaborations increase, the secured funds are expected to gradually convert into R&D and production orders for preclinical CROs, clinical CROs, and CDMOs, driving the CXO industry into an upturn cycle of rising order volumes and prices.

According to Wind data, as of April 10 this year, foreign institutions have conducted nearly 1,400 investigations into Shanghai-listed companies, covering approximately 190 firms. The focus is concentrated in semiconductors, high-end equipment, intelligent hardware, and innovative drugs. STAR Market companies are particularly favored, especially AI and chip-related sectors, which have become key focus areas for foreign capital. Different types of foreign institutions are simultaneously deepening their research and tracking of Shanghai-listed companies.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.